Kazakhstan vs Kyrgyzstan: Access to anti-retroviral drugs, female
Kazakhstan
60.0%
in 2024
Kyrgyzstan
60.0%
in 2024
Kazakhstan rank
103rd
Kyrgyzstan rank
103rd
Access to anti-retroviral drugs, female over time
- Kazakhstan
- Kyrgyzstan
How they compare
Kazakhstan currently reports 60.0% against 60.0% in Kyrgyzstan, a difference of 0.0%.
The two have swapped places 2 times across 25 shared years of data; in 2000 it was Kyrgyzstan ahead.
Kazakhstan ranks 103rd and Kyrgyzstan ranks 103rd of 141 countries.
Across the 3 decades both report, Kazakhstan averaged higher in 1 and Kyrgyzstan in 2.
Head to head by decade
| Decade | Kazakhstan | Kyrgyzstan | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 1.3% | 0.7% | 0.6% | Kazakhstan |
| 2010s | 21.3% | 26.4% | 5.1% | Kyrgyzstan |
| 2020s | 54.0% | 54.8% | 0.8% | Kyrgyzstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Kazakhstan or Kyrgyzstan?
- Kazakhstan, at 60.0% against 60.0% in Kyrgyzstan as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Kazakhstan and Kyrgyzstan?
- 0.0%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Kyrgyzstan?
- 25 years are reported by both, from 2000 to 2024.
- How do Kazakhstan and Kyrgyzstan rank globally for access to anti-retroviral drugs, female?
- Kazakhstan ranks 103rd and Kyrgyzstan ranks 103rd of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.